Evaluation of Long-term efficacy, safety and predictors of Adalimumab in Crohn's disease: Japanese multicenter cohort study (ADJUST study)

Evaluation of Long-term efficacy, safety and predictors of Adalimumab in Crohn's disease: Japanese multicenter cohort study (ADJUST study) - Evaluation of Adalimumab in Crohn's disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014708

Enrollment

500

Registered

2014-07-30

Start date

2014-07-30

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: All the Crohn's disease patients who were injected adalimumab from 27 October 2010 to 31 December 2013.

Exclusion criteria

Exclusion criteria: Nothing

Design outcomes

Primary

Measure	Time frame
Rate of ongoing adalimumab treatment.	—

Secondary

Measure	Time frame
Rate of ongoing adalimumab treatment and the predictors. Rate of non ileo-colonic resection after adalimumab treatment and the predictors. Reason of adalimumab drop out. Adverse event. etc	—

Countries

Japan

Contacts

Public ContactHiroki Tanaka

Sapporo Kosei General Hospital IBD Center

hirokit@mtc.biglobe.ne.jp011-261-5331

Outcome results